STOCK TITAN

Crispr Therapeut - CRSP STOCK NEWS

Welcome to our dedicated page for Crispr Therapeut news (Ticker: CRSP), a resource for investors and traders seeking the latest updates and insights on Crispr Therapeut stock.

Overview of CRISPR Therapeutics (CRSP)

CRISPR Therapeutics is a prominent biopharmaceutical company at the forefront of gene editing innovation. Utilizing its proprietary CRISPR/Cas9 platform, the company pioneers precise and transformative gene-based medicines aimed at treating serious, genetically defined diseases. With strategic emphasis on gene editing, transformative therapeutics, and precision medicine, CRISPR Therapeutics has established a unique position in the biotechnology ecosystem.

Core Technology and Scientific Foundation

The backbone of CRISPR Therapeutics is the revolutionary CRISPR/Cas9 system, a cutting-edge technology that allows for direct, accurate modifications to genomic DNA. This approach involves leveraging an RNA-guided DNA endonuclease to target specific gene sequences, facilitating edits that can correct genetic anomalies. The platform’s precision and adaptability have opened new avenues for addressing diseases that were previously considered intractable.

Therapeutic Programs and Disease Areas

The company has a comprehensive portfolio of therapeutic programs spanning multiple disease areas. Its research and clinical efforts concentrate on:

  • Hemoglobinopathies: Programs designed to modify genetic sequences critical to conditions such as sickle cell disease and transfusion-dependent beta-thalassemia, aiming to restore normal hemoglobin production.
  • Oncology and Immuno-Oncology: Advanced cell therapies, including allogeneic CAR T therapies, target various hematologic malignancies by harnessing the immune system to recognize and eradicate cancer cells.
  • Regenerative Medicine: Development of innovative approaches for tissue repair and regeneration, leveraging stem cell-derived therapies for diseases like Type 1 diabetes.
  • Rare and Autoimmune Diseases: Precision gene editing enables tailored interventions for underserved patient populations facing high unmet medical needs.

This diversified approach not only addresses a wide range of conditions but also underscores the company’s commitment to exploring the full potential of gene editing in medicine.

Collaborative Partnerships and Global Footprint

Recognizing the complexities underlying gene-based therapies, CRISPR Therapeutics has forged robust strategic collaborations with leading industry partners. These alliances facilitate accelerated development, manufacturing, and commercialization of transformative therapeutics. The company operates on a global scale, with research and development centers, as well as business offices strategically positioned across key regions in North America and Europe, ensuring its innovations reach a broad patient base.

Research and Development Excellence

With a strong focus on R&D, the company continuously refines its CRISPR/Cas9 platform and explores next-generation gene editing tools and delivery systems. Its ongoing clinical trials and investigational programs provide crucial insights into safety, efficacy, and the therapeutic potential of its candidates. This research-driven approach, combined with a rigorous scientific methodology, helps solidify the company’s reputation as an authority in the field of gene editing.

Industry Relevance and Competitive Positioning

CRISPR Therapeutics exemplifies technological mastery in the fast-evolving field of biomedicine. Its innovative platform not only catalyzes new treatment paradigms but also redefines standards for precision and safety in gene therapy. The company’s comprehensive development programs, coupled with its strategic partnerships, position it distinctly within a competitive landscape that includes other advanced biopharmaceutical innovators. Its methodical approach to research and a deep understanding of clinical challenges underscore its commitment to addressing some of the most daunting medical conditions.

Business Model and Market Strategy

The core of CRISPR Therapeutics' business model lies in its robust scientific platform, which supports a pipeline of diverse gene-editing programs. The company carefully balances in-house research with external collaborations to de-risk development and optimize resource allocation. By focusing on therapeutic areas with significant unmet needs, it targets markets where precision medicine can have the most pronounced impact. This integrated strategy ensures that CRISPR Therapeutics remains both innovative and adaptable to changing industry dynamics.

Commitment to Precision, Expertise, and Transparency

Transparency in scientific inquiry and commitment to regulatory rigor form the cornerstone of the company’s ethos. CRISPR Therapeutics approaches each clinical challenge with detailed risk assessments and well-defined safety profiles, ensuring that its innovations are both scientifically robust and ethically grounded. Such diligence not only reinforces its credibility but also instills confidence among stakeholders and the broader medical community.

Concluding Insights

In summary, CRISPR Therapeutics stands as a seminal player in the gene editing landscape, blending groundbreaking science with a strategic, diversified approach to disease treatment. Its focus on deploying the CRISPR/Cas9 platform across multiple therapeutic areas reflects both scientific ingenuity and a commitment to addressing complex medical challenges. For anyone seeking a comprehensive understanding of its business, the company provides an exemplary case study in translating gene editing technology into tangible, life-changing treatments.

Rhea-AI Summary
CRISPR Therapeutics (Nasdaq: CRSP) provided an update on its immuno-oncology pipeline, focusing on next-generation CAR T product candidates CTX112™ targeting CD19 and CTX131™ targeting CD70. Preliminary data from ongoing clinical trials suggest that these candidates may improve upon the clinical profile of first-generation candidates CTX110 and CTX130, with increased CAR T cell expansion and functional persistence. The Company is transitioning patients treated with CTX110 and CTX130 to long-term follow-up and plans to expand trials of CTX112 into autoimmune disease and CTX131 into hematologic malignancies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.27%
Tags
none
-
Rhea-AI Summary
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) announced the first regulatory authorization of a CRISPR-based gene-editing therapy in the world. The United Kingdom's Medicines and Healthcare products Regulatory Agency (MHRA) has granted conditional marketing authorization for CASGEVY, a CRISPR/Cas9 gene-edited therapy, for the treatment of sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT). The therapy is indicated for eligible patients 12 years of age and older. CASGEVY has been authorized for the treatment of patients with recurrent vaso-occlusive crises or TDT, for whom a human leukocyte antigen (HLA) matched related hematopoietic stem cell donor is not available. The safety profile of patients treated with CASGEVY in clinical trials is generally consistent with myeloablative conditioning with busulfan and hematopoietic stem cell transplant.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.32%
Tags
none
-
Rhea-AI Summary
CRISPR Therapeutics completes Advisory Committee meeting for exa-cel for severe sickle cell disease (SCD) and assigns Prescription Drug User Fee Act (PDUFA) target action dates for SCD and transfusion-dependent beta thalassemia (TDT). Ongoing clinical trials for CAR T product candidates targeting B-cell malignancies, T cell malignancies and solid tumors. Also, clinical trials ongoing for VCTX211 for Type 1 Diabetes and CTX310 targeting angiopoietin-related protein 3 (ANGPTL3).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.57%
Tags
Rhea-AI Summary
CRISPR Therapeutics announces preclinical data from investigational programs for cardiovascular disease treatment. CTX310™ shows durable reductions in ANGPTL3 protein and triglyceride levels in non-human primates after a single dose. CTX320™ shows durable reductions in lipoprotein(a) levels in non-human primates after a single dose. Clinical trial initiated for CTX310™, targeting ANGPTL3. CTX320™ targeting Lp(a) is on track to enter the clinic in the first half of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.16%
Tags
-
Rhea-AI Summary
CRISPR Therapeutics announced the completion of the FDA's advisory committee meeting for exa-cel, a potential therapy for severe sickle cell disease (SCD). The PDUFA target action date for SCD is December 8, 2023. If approved, exa-cel could be the first genetic therapy available to approximately 20,000 people with severe SCD in the U.S. The BLA for transfusion-dependent beta-thalassemia (TDT) has a PDUFA date of March 30, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.38%
Tags
none
-
Rhea-AI Summary
CRISPR Therapeutics (Nasdaq: CRSP) announces trading halt as FDA reviews Biologics License Application for exagamglogene autotemcel (exa-cel) for sickle cell disease treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
CRISPR Therapeutics announces poster presentations of preclinical data at SITC 38th Annual Meeting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.21%
Tags
conferences
-
Rhea-AI Summary
CRISPR Therapeutics co-founder, Rodger Novak, M.D., to step down as President and Chairman, effective September 15, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.43%
Tags
management
-
Rhea-AI Summary
CRISPR Therapeutics to participate in fireside chat at Citi's Biopharma Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.1%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.74%
Tags

FAQ

What is the current stock price of Crispr Therapeut (CRSP)?

The current stock price of Crispr Therapeut (CRSP) is $32.65 as of April 4, 2025.

What is the market cap of Crispr Therapeut (CRSP)?

The market cap of Crispr Therapeut (CRSP) is approximately 2.8B.

What is CRISPR Therapeutics' primary focus?

CRISPR Therapeutics focuses on developing gene-based medicines using its proprietary CRISPR/Cas9 technology to treat serious, genetically defined diseases.

How does the CRISPR/Cas9 platform work?

The CRISPR/Cas9 platform utilizes a precise RNA-guided mechanism to target and edit specific DNA sequences, enabling precise modifications to correct genetic defects.

Which therapeutic areas does the company target?

The company’s programs span hemoglobinopathies, oncology, regenerative medicine, autoimmune disorders, cardiovascular conditions, and various rare diseases.

How does CRISPR Therapeutics generate revenue?

The company leverages a mix of in-house research and strategic collaborations with industry leaders, driving revenue through licensing arrangements, development partnerships, and commercialization of its gene editing therapies.

Who are CRISPR Therapeutics' strategic partners?

CRISPR Therapeutics collaborates with renowned companies in the biopharmaceutical sector, enhancing its R&D and commercialization capabilities through partnerships with industry leaders.

What distinguishes CRISPR Therapeutics in the competitive landscape?

Its pioneering CRISPR/Cas9 platform, robust pipeline of diverse gene editing therapies, and strategic global collaborations set it apart as an innovative and technically sophisticated player.

How does the company ensure scientific and clinical rigor?

CRISPR Therapeutics maintains a strong commitment to research excellence, incorporating extensive clinical trials and regulatory standards to ensure the safety and efficacy of its therapies.

What are the core elements of its business model?

The business model centers on leveraging a state-of-the-art gene editing platform, partnering with established industry players, and targeting therapeutic areas with high unmet needs to optimize clinical outcomes.

How is CRISPR Therapeutics contributing to innovation in medicine?

Through its disruptive gene editing technology, comprehensive clinical programs, and strategic collaborations, the company is driving forward a new class of transformative and precision-based treatments.
Crispr Therapeut

Nasdaq:CRSP

CRSP Rankings

CRSP Stock Data

2.77B
84.28M
1.67%
77.72%
24.26%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
Switzerland
ZUG